Table 1.
Rat-specific primer pair sequence for real-time PCR.
Figure 1.
Changes in the fold increase expression levels of (A) cytokines (TNFα, IL-6, IL-10, IL-1β, and TGF-1β) (B) myogenic response factors (MyoD1, Myf5, Pax7, Myogenin and Mrf4) and (C) growth factors (VEGF-A and IGF-1Eb) mRNA in skeletal muscle treated or not with PRP during the experimental period (at day 2 and 5).
The y-axis for all graphs represents the fold-difference relative to the Ctrl group. * represents significant difference between injured compared with the Ctrl group (p<0.05). § represents a significant difference between the PRP-injury treated group and the NO PRP-injury treated group (p<0.05). Values are means ± SEM (n = 5 rats/group at each time point). Dashed line represents the base line control group.
Figure 2.
Effects of PRP on total MyoD1 (A) and Myogenin (B) protein expression in uninjured skeletal muscle of rat (Ctrl), injured-PRP treated (PRP group) or not PRP treated (NO-PRP group) at different times post-injury (at day 2 and 5).
The relative protein expression was determined by the ratio of the sample value to an internal standard control (GAPDH). Values are means ± SEM (n = 5 rats/group at each time point). * represents a significant difference between injured groups and the Ctrl group (p<0.05). § represents a significant difference between PRP-injury treated groups and NO PRP-injury treated groups (p<0.05).
Figure 3.
Immunohistochemical analysis of (A) MyoD1-positive or (C) Pax7-positive nuclei in skeletal muscle injury treated or not with PRP.
Representative double-immunoflorescence staining of skeletal muscle for (B) MyoD1 (green) and laminin (red) or (D) Pax7 (green) and laminin (red), at day 2- and 5, respectively. Myonuclei were counterstained by blue fluorescent dyes (Hoechst). The percentage of MyoD1-positive or Pax7-positive cells was calculated as the ratio of the number of nuclei in MyoD1- or Pax7 positive cells over that of Hoechst-positive nuclei. Results were presented as means ± SEM from n = 5 rats/group per time point and on five sections from each animal. Scale bars = 50 µm. * p<0.05 vs. Ctrl group. §p<0.05 vs. NO-PRP group.
Figure 4.
Real time-PCR analysis of miR-1, miR-133a and miR-206 expression using total RNA isolated from Ctrl-, PRP- and NO-PRP- group at 2 (A) and 5 (B) day post-injury.
C) Western blot analysis of SRF protein expression in skeletal muscle at 2- and 5-day post-injury. The histograms represent fold change expression calculated as means ± SEM (n = 5 rats/group at each time point) respect to the Ctrl group. *p<0.05 vs. Ctrl group. §p<0.05 vs. 5d NO-PRP group. Dashed line represents the base line Ctrl group.
Figure 5.
Effects of PRP on (A) p38MAPK, (B) ERK activity and (C) AKT tot at 2- and 5-day post-injury in regenerating skeletal muscle.
Bar diagrams representing the densitometric intensities of p-p38MAPK, pERK1/2 and AKT tot normalized with those for p38MAPK, ERK and GAPDH content, respectively. Results were presented as means ± SEM from n = 5 rats/group per time point. *p<0.05 vs. Ctrl group. §p<0.05 vs. NO-PRP group.
Figure 6.
Effect of PRP treatment on several HSPs during regeneration process (2- and 5-day post-injury).
(A) Representative immunoblot of each protein marker reported. (B) αB-crystallin; (C) S59 phospho-αB-crystallin; (D) Hsp27; (E) S82 phpspho-Hsp27; (F) Hsp70. Each bar represents mean value ± SEM (n = 5/group at each point). * p<0.05 vs. Ctrl group.§ p<0.05 vs. 5d NO-PRP group.
Figure 7.
Effect of PRP treatment on several apoptotic markers during regeneration process (2- and 5-day postinjury).
(A) Representative immunoblot of each protein marker reported; (B) NF-κB-p65, and (C) Bax/Bcl-2 ratio. Values are means ± SEM (n = 5/group at each point). * p< 0.05 vs. Ctrl group.§ p< 0.05 vs. 5d NO-PRP group.
Figure 8.
Model of PRP-mediated regulation of skeletal muscle healing.
The presence of PRP modulated the expression of miR-133a and SRF protein as well as several myogenic response factors such as MyoD1, Pax7, and Myf5, the growth factor IGF-1Eb and both the cytokine IL-1β and TGF-1β. The modulation of these factors may affect important physiological processes such as the inflammatory response, myoblast proliferation and differentiation, production of extracellular matrix, and myoblast apoptosis.
Figure 9.
Schematic representation of the role of αB-crystallin and Hsp27 in the myofiber stabilization and in cytoprotection following skeletal muscle injury.
The presence of PRP enhances phosphorylation of Ser-59 of αB-crystallin, which binds myofilaments and the inactive precursor of caspase 3, causing their stabilization and inhibition of apoptosis. Further, phospho Ser-59 αB-crystallin enhances NF-κB-p65 activation which may contribute to increased cell survival during regeneration process.